City of Hope is recognized internationally for its breakthrough research discoveries and clinical trials for developing new ways to treat hematologic cancers. Patients at City of Hope will have the ability to enroll in these trials, which can expand their treatment options and improve their outcomes.
Highlights of our current efforts include:
While stem cell transplants can be a lifesaving procedure for patients with hematologic disorders, it also carries a risk of graft versus host disease (GvHD), in which the newly transplanted stem cells do not recognize the recipient’s body as their own and start producing an immune response against it, leading to chronic and potentially serious complications. To reduce the likelihood of GvHD and to improve transplant outcomes, City of Hope is researching new ways to classify and match stem cell donors and recipients.
Harnessing the patient’s own immune system against the cancer, specifically through T-cell modification. In this experimental therapy, the patient’s own T-cells are extracted from the body, modified to recognize and attack cancer cells and re-infused back into the patient. This treatment has shown positive results for patients with
and is currently being studied for its potential against myeloid leukemia and
Our use and refinement of nonmyeloablative (“mini”) transplants, which relies less on the heavy doses of chemotherapy and radiation and more on the anti-cancer effects of the transplant itself. This novel approach allows otherwise ineligible patients, such as older patients or those who cannot tolerate radiation/chemotherapy-related effects, to be treated with this lifesaving procedure.
Continual development and improvement of drug regimens to treat hematologic cancers. Recently, City of Hope had led a national study of the drug brentuximab in patients with relapsed
, in whom the drug produced a high rate of response compared to standard therapy.
Our scientists are currently investigating leukemia stem cells, which several studies have suggested to cause leukemia. By identifying and eradicating these cancerous stem cells — instead of just the mature leukemia cells that conventional therapies target — a definitive cure for this disease can be achieved.
If you have been diagnosed with a hematologic cancer or are looking for a second opinion consultation about your treatment, find out more about
becoming a patient
or contact us at 800-826-HOPE.